

Edgar Filing: TRANSGENOMIC INC - Form 8-K

TRANSGENOMIC INC  
Form 8-K  
April 20, 2005

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
April 20, 2005

TRANSGENOMIC, INC.  
(Exact name of registrant as specified in its charter)

Delaware  
(State of Formation) 000-30975  
(Commission File Number)

911789357  
(IRS Employer Identification Number)

12325 Emmet Street  
Omaha, NE 68164  
(Address of principal executive offices) (Zip Code)

(402) 452-5400  
(Registrants' telephone number, including area code)

Not applicable  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to  
simultaneously satisfy the filing obligation of the registrant under any of the  
following provisions:

- Written communications pursuant to Rule 425 under the Securities Act  
(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act  
(17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange  
Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange  
Act (17 CFR 240.13e(c))

=====

ITEM 8.01 OTHER EVENTS.

On Wednesday, April 20, 2005, the Company issued a press release  
announcing it has agreed to provide additional quantities of modified nucleic

Edgar Filing: TRANSGENOMIC INC - Form 8-K

acid building block compounds to Geron Corporation under terms of a new addendum to an existing Master Supply Agreement between the two companies. A copy of the press release is filed herewith as Item 9.01 and is incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Press Release, dated April 20, 2005, announcing that the Company has agreed to provide additional quantities of modified nucleic acid building block compounds to Geron Corporation under terms of a new addendum to an existing Master Supply Agreement between the two companies.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRANSGENOMIC, INC.

By /s/ Mitchell L. Murphy

-----  
Michael Summers  
VP, Secretary & Treasurer

April 20, 2005

3